H.C. Wainwright Reaffirms Buy on argenx (ARGX), Highlights Pipeline Progress

argenx SE (NASDAQ:ARGX) is one of the high growth stocks outside tech analysts are bullish on. H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating on argenx SE (NASDAQ:ARGX) as of July 1, citing strong progress in the company’s neuromuscular treatment pipeline. With a current market price of $598.40 and Bank of America’s price target of $804, the stock offers a potential upside of about 34.3%.

ChatGPT said: H.C. Wainwright Reaffirms Buy on argenx (ARGX), Highlights Pipeline Progress

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

The bullish stance is driven by the advancement of ARGX-119, now entering a registrational trial for congenital myasthenic syndromes (CMS). This marks the company’s third molecule to reach late-stage clinical development. Positive Phase 1b results showed promising safety and consistent improvements in patient outcomes, which boosted investor confidence.

ARGX-119 also highlights the growing potential of argenx’s SIMPLE Antibody platform, a proprietary technology for developing precise antibody-based therapies. The ongoing natural history study in CMS is expected to add valuable, real-world insight that could support regulatory submissions.

The company is also conducting a Phase 2a study of ARGX-119 in amyotrophic lateral sclerosis (ALS), a move that could broaden its future treatment offerings. If successful, ARGX-119 could become the first therapy approved for DOK7-CMS, a very rare form of neuromuscular disease.

argenx develops antibody-based therapies for rare autoimmune and neuromuscular disorders.

While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Most Profitable Consumer Stocks to Buy Now and 10 Best High-Margin Pharma Stocks to Buy Now.

Disclosure: None.